HC Wainwright & Co. Reiterates Buy on IO Biotech, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on IO Biotech (NASDAQ:IOBT), but lowered the price target from $11 to $8.
August 11, 2023 | 5:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
IO Biotech's price target has been lowered from $11 to $8 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially lead to a short-term negative impact on IO Biotech's stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100